Ceftolozane–tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series

Ceftolozane–tazobactam (CT) is a recently approved novel cephalosporin and β-lactamase inhibitor combination agent with in vitro activity against various Gram-positive and Gram-negative pathogens, including several multidrug-resistant (MDR) Gram-negative organisms. CT is currently approved by the US...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xing Tan, Ryan P. Moenster
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2019
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/982b73dfcb534ff0a6e19da8767df082
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:982b73dfcb534ff0a6e19da8767df082
record_format	dspace
spelling	oai:doaj.org-article:982b73dfcb534ff0a6e19da8767df0822021-12-02T04:33:19ZCeftolozane–tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series2042-099410.1177/2042098619862083https://doaj.org/article/982b73dfcb534ff0a6e19da8767df0822019-07-01T00:00:00Zhttps://doi.org/10.1177/2042098619862083https://doaj.org/toc/2042-0994Ceftolozane–tazobactam (CT) is a recently approved novel cephalosporin and β-lactamase inhibitor combination agent with in vitro activity against various Gram-positive and Gram-negative pathogens, including several multidrug-resistant (MDR) Gram-negative organisms. CT is currently approved by the US Food and Drug Administration for the treatment of complicated intrabdominal infection and complicated urinary tract infection at a dose of 1.5 g intravenously every 8 h. This agent is an attractive option for MDR osteomyelitis (OM) treatment, but clinical data is limited to case reports and series. Here we report a series of five patients with MDR OM who were treated with CT. Pathogens involved in these infections were MDR Acinetobacter baumannii (two isolates) and MDR Pseudomonas aeruginosa (four isolates). Two patients were disease free 6 months after therapy was discontinued, one required an additional curative surgical procedure, and two (both on high-dose therapy) developed adverse reactions likely related to CT that necessitated early antibiotic discontinuation.Xing TanRyan P. MoensterSAGE PublishingarticleTherapeutics. PharmacologyRM1-950ENTherapeutic Advances in Drug Safety, Vol 10 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Xing Tan Ryan P. Moenster Ceftolozane–tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series
description	Ceftolozane–tazobactam (CT) is a recently approved novel cephalosporin and β-lactamase inhibitor combination agent with in vitro activity against various Gram-positive and Gram-negative pathogens, including several multidrug-resistant (MDR) Gram-negative organisms. CT is currently approved by the US Food and Drug Administration for the treatment of complicated intrabdominal infection and complicated urinary tract infection at a dose of 1.5 g intravenously every 8 h. This agent is an attractive option for MDR osteomyelitis (OM) treatment, but clinical data is limited to case reports and series. Here we report a series of five patients with MDR OM who were treated with CT. Pathogens involved in these infections were MDR Acinetobacter baumannii (two isolates) and MDR Pseudomonas aeruginosa (four isolates). Two patients were disease free 6 months after therapy was discontinued, one required an additional curative surgical procedure, and two (both on high-dose therapy) developed adverse reactions likely related to CT that necessitated early antibiotic discontinuation.
format	article
author	Xing Tan Ryan P. Moenster
author_facet	Xing Tan Ryan P. Moenster
author_sort	Xing Tan
title	Ceftolozane–tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series
title_short	Ceftolozane–tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series
title_full	Ceftolozane–tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series
title_fullStr	Ceftolozane–tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series
title_full_unstemmed	Ceftolozane–tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series
title_sort	ceftolozane–tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series
publisher	SAGE Publishing
publishDate	2019
url	https://doaj.org/article/982b73dfcb534ff0a6e19da8767df082
work_keys_str_mv	AT xingtan ceftolozanetazobactamforthetreatmentofosteomyelitiscausedbymultidrugresistantpathogensacaseseries AT ryanpmoenster ceftolozanetazobactamforthetreatmentofosteomyelitiscausedbymultidrugresistantpathogensacaseseries
_version_	1718401203626311680

Ceftolozane–tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series

Ejemplares similares